Skip to main navigation

About
- Summary
- Leadership
Science
- Our Science
- Publications
Platform
Pipeline
Patients
Investors
Join Our Team
- Openings
- Life at Foghorn
Contact

Media

Overview
News
- Press Releases
- Media
Events & Presentations
- Events
- Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Info
- FAQ
- Contact

Filter by Year:

ALL

2022

2021

2020

2019

2018

2017

2015

BIOSPACE

Foghorn and Merck Ink Strategic Collaboration in Cancer for $425 Million+

July 8, 2020

XCONOMY

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

July 8, 2020

FIERCE BIOTECH

Merck teams up with cancer startup Foghorn in $425M deal

July 8, 2020

ENDPOINTS NEWS

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

July 8, 2020

BIOTECH 2050

Podcast Ep. 9 – Carl P. Decicco, PhD, Chief Scientific Officer, Foghorn Therapeutics

January 23, 2020

Print
RSS Feeds
Email Alerts
Investor Contact
Search

© 2024 Foghorn Therapeutics. All rights reserved.

Terms of Use

info@foghorntx.com